X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Torrent Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs TORRENT PHARMA - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA TORRENT PHARMA CIPLA/
TORRENT PHARMA
 
P/E (TTM) x 44.7 27.7 161.7% View Chart
P/BV x 3.8 5.3 72.9% View Chart
Dividend Yield % 0.3 1.0 32.3%  

Financials

 CIPLA   TORRENT PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-17
TORRENT PHARMA
Mar-17
CIPLA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs6221,768 35.2%   
Low Rs4581,186 38.7%   
Sales per share (Unadj.) Rs181.9346.1 52.5%  
Earnings per share (Unadj.) Rs12.955.2 23.3%  
Cash flow per share (Unadj.) Rs29.373.3 40.0%  
Dividends per share (Unadj.) Rs2.0014.00 14.3%  
Dividend yield (eoy) %0.40.9 39.1%  
Book value per share (Unadj.) Rs155.7257.1 60.6%  
Shares outstanding (eoy) m804.51169.22 475.4%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.04.3 69.6%   
Avg P/E ratio x42.026.8 156.8%  
P/CF ratio (eoy) x18.420.1 91.5%  
Price / Book Value ratio x3.55.7 60.4%  
Dividend payout %15.525.4 61.2%   
Avg Mkt Cap Rs m434,516249,887 173.9%   
No. of employees `00023.011.8 195.6%   
Total wages/salary Rs m26,3389,934 265.1%   
Avg. sales/employee Rs Th6,349.14,971.5 127.7%   
Avg. wages/employee Rs Th1,143.0843.2 135.6%   
Avg. net profit/employee Rs Th449.3792.4 56.7%   
INCOME DATA
Net Sales Rs m146,30258,569 249.8%  
Other income Rs m2,2872,233 102.4%   
Total revenues Rs m148,58960,802 244.4%   
Gross profit Rs m24,75813,773 179.8%  
Depreciation Rs m13,2293,069 431.0%   
Interest Rs m1,5942,056 77.5%   
Profit before tax Rs m12,22210,881 112.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,7981,545 116.3%   
Profit after tax Rs m10,3549,336 110.9%  
Gross profit margin %16.923.5 72.0%  
Effective tax rate %14.714.2 103.6%   
Net profit margin %7.115.9 44.4%  
BALANCE SHEET DATA
Current assets Rs m87,37053,841 162.3%   
Current liabilities Rs m33,08131,612 104.6%   
Net working cap to sales %37.138.0 97.8%  
Current ratio x2.61.7 155.1%  
Inventory Days Days8797 89.5%  
Debtors Days Days6284 74.4%  
Net fixed assets Rs m111,56742,079 265.1%   
Share capital Rs m1,609846 190.1%   
"Free" reserves Rs m123,64542,655 289.9%   
Net worth Rs m125,25443,501 287.9%   
Long term debt Rs m36,45422,408 162.7%   
Total assets Rs m209,532101,250 206.9%  
Interest coverage x8.76.3 137.7%   
Debt to equity ratio x0.30.5 56.5%  
Sales to assets ratio x0.70.6 120.7%   
Return on assets %5.711.3 50.7%  
Return on equity %8.321.5 38.5%  
Return on capital %8.519.6 43.3%  
Exports to sales %34.20-   
Imports to sales %8.30-   
Exports (fob) Rs m50,050NA-   
Imports (cif) Rs m12,203NA-   
Fx inflow Rs m51,06620,066 254.5%   
Fx outflow Rs m17,6785,304 333.3%   
Net fx Rs m33,38814,762 226.2%   
CASH FLOW
From Operations Rs m23,82410,127 235.2%  
From Investments Rs m-13,127-7,869 166.8%  
From Financial Activity Rs m-13,239-1,918 690.2%  
Net Cashflow Rs m-2,478212 -1,171.6%  

Share Holding

Indian Promoters % 16.0 71.5 22.4%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 7.0 173.8%  
FIIs % 23.7 12.6 188.1%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 8.8 297.7%  
Shareholders   161,166 26,511 607.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   DISHMAN PHARMA  ELDER PHARMA  ALEMBIC LTD  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Firm; IT Stocks Gain(09:30 am)

Asian stocks were relatively subdued in the early trade today, with most regional indices hovering around the flat line following the softer lead stateside.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Feb 21, 2018 10:47 AM

TRACK CIPLA

CIPLA - DISHMAN PHARMA COMPARISON

COMPARE CIPLA WITH

MARKET STATS